The company's proprietary PASylation platform alters the pharmacokinetics of peptides to create long-acting analogs that target chronic cardiovascular, metabolic, and endocrine diseases. Antlia Bioscience's drug candidates are based on clinically validated preexisting biology, resulting in high-value and low-risk therapeutic options.